Covid-19: Russian Vaccine Shows Signs Of Antibody Response, Says Lancet Study

Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.

Russian researchers have published first report on their Covid-19 vaccine in the medical journal The Lancet.

The report says that early tests were found to show signs of an immune response. None of the Covid patients showed any serious side effects, the report, published in the journal, said.

In August, Russia became the first country to license the coronavirus vaccine for public use. The move to approve Sputnik V for public use by the Russian authority was criticised by the health experts because Russia had gone ahead with its Covid vaccine plan without publishing any data about the safety and effectiveness of its vaccine.

Last month, President Vladimir Putin said the vaccine had passed all the required checks and that one of his own daughters had been given it.

Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.

The scientists designed a COVID-19 vaccine with two different adenoviral vectors (recombinant Ad26 [rAd26] and recombinant Ad5 [rAd5]), both carrying the gene for SARS-CoV-2 spike glycoprotein (rAd26-S and rAd5-S), and  implemented a prime-boost regimen.

The trials were open label and not randomised. No placebo was involved in the trial. All volunteers who participate in the trial knew that they were receiving the vaccine shot.

“Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection,” the report said.

“When adenovirus vaccines enter people’s cells, they deliver the SARS-CoV-2 spike protein genetic code, which causes cells to produce the spike protein,” said study lead author Denis Logunov, from Gamaleya National Research Centre for Epidemiology and Microbiology, Russia.

“This helps teach the immune system to recognise and attack the SARS-CoV-2 virus. To form a powerful immune response against SARS-CoV-2, it is important that a booster vaccination is provided,” Logunov said.

Interpretation

The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.

Meanwhil, Kirill Dmitriev, CEO, Russian Direct Investment Fund said yesterday, “We are having close dialogue with corresponding ministries and Indian government and its leading manufactures regarding localisation of production of Sputnik V vaccine”.

Facebook Comments